Table 1.
Baseline characteristics of HCV-infected patients undergoing DAA treatment.
| Patients, no. | 113 |
|---|---|
| M/F | 57 (50.4%)/56 (49.6%) |
| Age, mean (years) | 66 |
| Chronic hepatitis C, no. | 87 (77%) |
| Cirrhosis, no. | 26 (23%) |
| Previous IFN-α treatment, no. | 30 (26.5%) |
| Pre-treatment HCV-RNA, median (range) | 4.35 x 106 UI/ml (1.3 x 102 – 7.5 x 107) |
| Pre-treatment Fibroscan, median (range) | 10.9 kPa (3.7- 42.5) |
| HCV genotype, % | |
| 1a | 11 |
| 1b | 52 |
| 2 | 29 |
| 3 | 6 |
| 4 | 2 |
| Comorbidities (%) | |
| hypertension | 39 |
| cardiovascular | 26 |
| hematologic | 20 |
| gastrointestinal | 20 |
| endocrine | 17 |
| diabetes | 15 |
| dermatologic | 13 |
| rheumatologic | 13 |
| pulmonary | 12 |
| neurologic | 12 |
| psychiatric | 10 |
| cancer | 5 |
| sense organs | 4 |